Phase 2 N=62 Pembrolizumab in Patients With Non-Small Cell Lung Cancer and a Performance Status 2
Carcinoma, Non-Small-Cell Lung
Primary: Toxicity Rate — 18; 42 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=30 Bacille Calmette-Guerin (BCG) Vaccine for Immune Protection Against Infections
Cystic Fibrosis · Bronchiectasis Adult · Non-Tuberculous Mycobacteria
Primary: BCG Uptake — 48.06; 0.84; 35.97 spot forming units
Phase 2 N=37 An Efficacy and Safety Study of a Combination of JNJ-73763989, Nucleos(t)Ide Analogs (NA), and a Programmed Cell Death Protein Receptor-1 (PD-1) Inhibitor in Chronic Hepatitis B Participants
Hepatitis B, Chronic
Primary: Percentage of Participants Who Achieved Hepatitis B Surface Antigen (HBsAg) Seroclearance at Follow-up (FU) Week 24 — 0; 0 Percentage of participants
Phase 2 N=72 A Study of Nivolumab Plus Brentuximab Vedotin in Patients Between 5 and 30 Years Old, With Hodgkin's Lymphoma (cHL), Relapsed or Refractory From First Line Treatment
Hodgkin Disease
Primary: Complete Metabolic Response (CMR) Rate at Any Time Prior to Radiation Therapy by Blinded Independent Centralized Review (BICR) - Cohort 1 — 92.9 Percent of participants
Phase 2 N=37 NB-001 in Children and Adolescents With 22q11 Deletion Syndrome
22q11 Deletion Syndrome
Primary: Safety and Tolerability of NB-001 — 18; 24; 14; 20 Participants
Phase 2 N=345 A Study of the Efficacy and Safety of MEDI7352 in Participants With Painful Osteoarthritis of the Knee
Painful Osteoarthritis of the Knee
Primary: Change From Baseline in Weekly Average of Daily Numerical Rating Scale (NRS) Pain Score to Week 12 — -2.19; -3.00; -2.83; -2.81 Unit on a scale — p=0.360
Phase 2 N=51 A Study Evaluating the Safety, Tolerability, and Pharmacodynamic Effects of GLY-200 in Type 2 Diabetic Patients
Type 2 Diabetes
Primary: Number of Participants With Adverse Events [Safety and Tolerability of GLY-200] — 9; 8; 12; 7 Participants
Phase 2 N=112 Impact of Lofexidine on Stress, Craving and Opioid Use
Opioid-use Disorder · Opiate Dependence
Primary: Drug Cue+ Stressor Induced Craving — 1.52; 1; 1.72; 1.96 units on a scale
Phase 2 N=172 A Study of Tiragolumab Plus Atezolizumab and Atezolizumab Monotherapy in Participants With Metastatic and/or Recurrent PD-L1-Positive Cervical Cancer
Cervical Cancer
Primary: Pre-crossover Period: Independent Review Committee (IRC)-Assessed Objective Response Rate (ORR) — 15.6; 19.0 percentage of participants
Phase 2 N=32 Intranasal Oxytocin vs. Placebo for the Treatment of Hyperphagia in Prader-Willi Syndrome
Prader-Willi Syndrome · Hyperphagia
Primary: Change in Efficacy of Peptide Intranasal Oxytocin (IN-OXT) — -6.08; -6.64 score on a scale
Phase 2 N=35 A Trial to Assess the Effect of Delgocitinib Cream 20 mg/g on the Molecular Signature, Safety, and Efficacy in Adults With Frontal Fibrosing Alopecia
Frontal Fibrosing Alopecia
Primary: Change in Expression of Chemokine (C-X-C Motif) Ligand 9 (CXCL9), Chemokine (C-X-C Motif) Ligand 10 (CXCL10), and Interferon (IFN)-γ From Baseline to Week 12. — -3.10…
Phase 2 N=73 Immune Basis and Clinical Implications of Threshold-based Phenotypes of Peanut Allergy
Food Allergy · Peanut Allergy
Primary: Percentage of Children That Tolerate the Full Challenge — 100; 21 percentage of participants
Phase 2 N=13 Study Assessing the Safety and Efficacy of Pegcetacoplan in Post-Transplant Recurrence of C3G or IC-MPGN
C3G · IC-MPGN · Renal Transplant
Primary: Percentage of Subjects With Reduction in C3c Staining on Renal Biopsy at Week 12 — 50.0; 33.3 Percentage of participants
Phase 2 N=60 A Study of Evaluating the Safety and Efficacy of ATG-010 in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Primary: ORR — 13 Participants
Phase 2 N=212 A Phase 2b Study of BNC210 Tablet Formulation in Adults With Post-Traumatic Stress Disorder (PTSD)
Post-Traumatic Stress Disorder
Primary: Change From Baseline on the Clinician Administered Post-Traumatic Stress Disorder (PTSD) Scale for the Diagnostic and Statistical Manual of Mental Disorders, Fifth…